The World Health Organisation has declared that antimicrobial resistance (AMR) is one of the top 10 global public health threats facing humanity. Around 70% of antibiotics are used in animal farming, exacerbating the AMR problem.Lysins are highly specific and fast acting protein based anti-bacterials which rapidly disrupt the cell wall of the bacterial target and to date have exhibit very low resistance development.

Objective/mission (The vision): The production of highly specific Lysins for human and animal treatment in microalgae to opens up a low cost oral delivery options.

Research approach (The initiative): The project will involve a wide range of molecular biology techniques, microalgal chloroplast based expression and scale up. Further opportunities exist in antimicrobial screening.

Impacts and applications: In Europe, it is estimated that antimicrobial resistance imposes a  Euro 9 billion cost burden year. In the United States, according to the Centers for Disease Control and Prevention (CDC), antimicrobial resistance imposes a $20 billion direct healthcare cost burden, and a  $35 billion dollar loss in annual productivity.

Partners/collaborators: IMB Centre for Superbug Solution, School of Dentistry

Project members

Key contacts

Professor Ben Hankamer

Professorial Research Fellow
Institute for Molecular Bioscience

Dr Melanie Oey

Research Fellow
Institute for Molecular Bioscience